Innovent Biologics, Inc. (HKG:1801)
Hong Kong
· Delayed Price · Currency is HKD 78.20
-0.40 (-0.51%)
Jun 19, 2025, 3:45 PM HKT
Innovent Biologics Revenue
In the year 2024, Innovent Biologics had annual revenue of 9.42B CNY with 51.82% growth. Innovent Biologics had revenue of 5.47B in the half year ending December 31, 2024, with 136.09% growth.
Revenue
9.42B CNY
Revenue Growth
+51.82%
P/S Ratio
12.95
Revenue / Employee
1.66M CNY
Employees
5,659
Market Cap
129.81B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines | 32.49B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| JD Health International | 61.89B |
| WuXi Biologics | 19.87B |
| CSPC Pharmaceutical Group | 28.99B |
| Sino Biopharmaceutical | 30.72B |
| Akeso | 2.26B |
| Alibaba Health Information Technology | 32.81B |
Innovent Biologics News
- 3 days ago - Innovent Announces Completion of First Participant Dosed in the Seventh Phase 3 Clinical Trial (GLORY-OSA) of Mazdutide in China - PRNewsWire
- 6 days ago - Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the ADA's 85th Scientific Sessions - PRNewsWire
- 14 days ago - Innovent's IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) Receives Second NMPA Breakthrough Therapy Designation for Immuno-resistant Squamous Non-Small Cell Lung Cancer - PRNewsWire
- 14 days ago - Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Renal Cell Carcinoma - PRNewsWire
- 15 days ago - 2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from the Phase 1 PoC Clinical Study in Advanced Non-small Cell Lung Cancer - PRNewsWire
- 16 days ago - 2025 ASCO Presentation: Innovent Biologics Announces Updated Data of IBI354 (Novel anti-HER2 ADC) From the Phase 1/2 Clinical Study in Advanced Ovarian Cancer, Breast Cancer and Other Solid Tumors - PRNewsWire
- 16 days ago - ASCO 2025 Oral Presentation: Innovent Biologics Announces Updated Data of IBI343 (Novel Anti-CLDN18.2 ADC) From the Phase 1 Clinical Study in Patients with Advanced Pancreatic Cancer - PRNewsWire
- 17 days ago - 2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Date of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from Phase 1 Clinical Studies in Advanced Colorectal Cancer - PRNewsWire